CH

Valtellina (Italy): The new Frontier of Gravel Cycling

Retrieved on: 
Donnerstag, Mai 9, 2024
Agriculture, Wine, Nature, Pizzoccheri, Grumello, Bitto, Water, History, Farmer, Culture, Tree, Wood, Stelvio National Park, Calendar

VALTELLINA, Italy, May 9, 2024 /PRNewswire/ -- Located in Northern Italy, between Lake Como and Switzerland, the alpine valley of Valtellina is not only about great alpine road-bike passes, or mountain-bike single-trails leading to the wilder sceneries. This summer in Valtellina is all about gravel cycling! Here history has left an immense heritage of roads related to agriculture and trading, that today are connected into itineraries suitable for any kind of cyclist.

Key Points: 
  • This summer in Valtellina is all about gravel cycling!
  • The main element is water: Sentiero Valtellina follows the Adda river, running along the whole valley from the alpine resort of Bormio to Lake Como (114 kilometers).
  • First date on the calendar (12 of May) and 1st edition for a gravel event with routes in the nature and culture of Valchiavenna.
  • Gravel is compelling and genuine, like the wine served as aperitif with rye bread and bresaola, like the farmers you meet on the roads.

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

Retrieved on: 
Donnerstag, Mai 9, 2024
CRSP, Webcast, Therapy, CRISPR Therapeutics, Bank, Conference

ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, at 12:20 p.m.

Key Points: 
  • ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, at 12:20 p.m.
  • ET.
  • A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events .
  • A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

Sportradar to Participate in the J.P. Morgan Global Technology, Media and Communications Conference on May 21

Retrieved on: 
Donnerstag, Mai 9, 2024
J. P. Morgan, Conference

ST. GALLEN, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company, today announced that Carsten Koerl, Chief Executive Officer, will participate in the J.P. Morgan 52nd Annual Global Technology, Media and Communications Conference at the Westin Boston Seaport District Hotel on Tuesday, May 21, 2024.

Key Points: 
  • ST. GALLEN, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company, today announced that Carsten Koerl, Chief Executive Officer, will participate in the J.P. Morgan 52nd Annual Global Technology, Media and Communications Conference at the Westin Boston Seaport District Hotel on Tuesday, May 21, 2024.
  • Mr. Koerl will participate in a fireside chat at 8:10 a.m. EST that morning and that will be webcast live on https://investors.sportradar.com .
  • Please contact your J.P. Morgan sales representative to register for the conference and to request a meeting with Sportradar management.

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Donnerstag, Mai 9, 2024
ADC, Conference, Webcast, Event

LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m.

Key Points: 
  • LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m.
  • ET.
  • A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website ir.adctherapeutics.com .
  • A replay of the webcast will be available for approximately 30 days.

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
Mittwoch, Mai 8, 2024
Sickle cell disease, T1D, SHR, Cell, CRISPR, Partnership, CD19, CRISPR Therapeutics, Biomarker, Autoimmunity, SCD, LNP, Lupus, Kingdom, Porphobilinogen, ADC, Eye, ANGPTL3, RAAS, PBG, Therapy, Lymphoid leukemia, Vertex Pharmaceuticals, Type 1 diabetes, Pain, Cas9, AHP, Diabetes, Research, ALA, BP, CD70, AGT, Clinical trial, Government, G&A, TDT, Sale, CRSP, ALAS1, European, Disease, Patient, Liver, Gene, Society, Stem cell, Cardiovascular disease, SLE, Pharmaceutical industry

CASGEVY is the first therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals established in 2015.

Key Points: 
  • CASGEVY is the first therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals established in 2015.
  • CRISPR Therapeutics has two next-generation approaches with the potential to significantly expand the addressable population with SCD and TDT.
  • G&A Expenses: General and administrative expenses were $18.0 million for the first quarter of 2024, compared to $22.4 million for the first quarter of 2023.
  • Collaboration Expense: Collaboration expense, net, was $47.0 million for the first quarter of 2024, compared to $42.2 million for the first quarter of 2023.

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

Retrieved on: 
Mittwoch, Mai 8, 2024
Pain, CRSP, Patient, SHR, Cas9, Cell, CRISPR, ALAS1, LNP, AHP, Gene editing, Angiotensin, Paratriathlon, RNA, IOP, ALA, Disease, Porphobilinogen, Liver, CRISPR Therapeutics, Gene, Eye, Society, Trabecular meshwork, MYOC, RAAS, Cardiovascular disease, BP, AGT, Biomarker, PBG, Therapy, Glaucoma

In addition, CRISPR Therapeutics announced the expansion of its in vivo pipeline with two new programs.

Key Points: 
  • In addition, CRISPR Therapeutics announced the expansion of its in vivo pipeline with two new programs.
  • “The expansion of our in vivo pipeline speaks to the scalability of the platform and the exceptional translation capabilities of our team.
  • The addition of two more programs, CTX340 and CTX450, utilizing this LNP delivery technology demonstrates the modularity and scalability of the platform.
  • In today’s presentation, the Company presented data demonstrating efficient and specific delivery to TM cells in mouse, non-human primate, and ex vivo human eyes.

Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis

Retrieved on: 
Mittwoch, Mai 8, 2024
Neuroprotection, Inflammation, Hospital, Safety, OCS, Diabetic retinopathy, Apoptosis, Optic neuritis, AON, IND, Disease, Patient, Paratriathlon, Geographic atrophy, Optic nerve, Neuron, Glaucoma, Ophthalmology, Neuro, Pharmaceutical industry

The Phase 2 ACUITY study is evaluating once-daily OCS-05 intravenous infusion in patients with AON.

Key Points: 
  • The Phase 2 ACUITY study is evaluating once-daily OCS-05 intravenous infusion in patients with AON.
  • OCS-05 has been granted orphan drug designation in both the United States and Europe, highlighting the importance of this unmet medical need.
  • In the meantime, we keep on working towards an IND submission for OCS-05 in the U.S. in 2024.
  • While corticosteroids are used to shorten the attack, there is no approved therapy for AON and unmet needs remain for therapies that can prevent vision loss after an acute episode of optic neuritis.

Oculis Reports Q1 2024 Financial Results and Provides Company Updates

Retrieved on: 
Mittwoch, Mai 8, 2024
Dexamethasone, Pain, State, Inflammation, Investment, Refractive surgery, Safety, NDA, OCS, Research, Cataract, DED, AON, Development, IND, Retina, ASCRS, Research and development, Patient, Society, Pharming, CHF, Genotype, DME, Bank statement, Clinical trial, Annual general meeting, Ophthalmology, Pharmaceutical industry

The two ongoing Phase 3 52-week trials, DIAMOND-1 and DIAMOND-2, started as planned in December 2023 and February 2024, respectively.

Key Points: 
  • The two ongoing Phase 3 52-week trials, DIAMOND-1 and DIAMOND-2, started as planned in December 2023 and February 2024, respectively.
  • Concurrently, the Company listed on the Nasdaq Iceland Main Market in addition to Nasdaq Global Market in the U.S.
    Snehal Shah, Pharm.
  • The Company also aims to complete an IND submission for OCS-05 in the U.S. in 2024.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.

Addex to Present at Bio€quity Europe 2024

Retrieved on: 
Mittwoch, Mai 8, 2024
Kursaal, SIX, Congress Center, Therapy

Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain.

Key Points: 
  • Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain.
  • In his in-person presentation, scheduled for 14:00 – 14:12 CEST, on Monday May 13, 2024 in Room 6 + 7, Mr. Dyer will provide a corporate update and discuss recent developments at Addex.
  • Mr. Dyer will be available for one-on-one meetings throughout the conference.
  • For more information or to schedule a one-on-one meeting, please contact [email protected] .

Hitachi Energy supports long-term operation of largest HVDC-connected wind energy project in U.S.

Retrieved on: 
Dienstag, Mai 7, 2024
Ecosystem, Operational excellence, VSC, Partnership, Electricity, Carbon, Pattern Energy, Hitachi, HVDC, Electric power

The link will connect the 3,515-megawatt (MW) SunZia Wind project in New Mexico to Arizona and Western states, which will be one of the world’s largest transmission links delivering renewable energy.

Key Points: 
  • The link will connect the 3,515-megawatt (MW) SunZia Wind project in New Mexico to Arizona and Western states, which will be one of the world’s largest transmission links delivering renewable energy.
  • The long-term agreement will provide service solutions for the SunZia Transmission HVDC link, currently under construction1, owned by Pattern Energy, one of the world’s largest privately-owned developers and operators of renewable energy and transmission projects.
  • Hitachi Energy’s HVDC Light® technology will efficiently transfer and integrate huge volumes of wind power over more than 885 kilometers (550 miles) into the regional power grid.
  • Hitachi Energy pioneered commercial HVDC technology 70 years ago and has delivered more than half of the world’s HVDC projects and has the largest installed base of HVDC in the world.